Eli Lilly and Co (FRA:LLY0) Beta: N/A (As of Jun. 27, 2026)


FRA:LLY0 Eli Lilly and Co FRA:LLY0
98 GF Score
Price €26.40
GF Value €30.80
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Eli Lilly and Co's Beta is Not available.

Eli Lilly and Co  (FRA:LLY0) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Eli Lilly and Co Beta Related Terms

Eli Lilly and Co Beta Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Beta Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:LLY0
98GF Score
Eli Lilly and Co FRA:LLY0
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Eli Lilly and Co (FRA:LLY0) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €26.40 is trading 14.3% below its estimated GF Value™ of €30.80. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for FRA:LLY0:

  • Beta: N/A
  • GF Value™: €30.80 vs. price of €26.40 (14.3% below fair value)
  • GF Score™: 98/100 with 6 warning signs

No single metric tells the full story. See the FRA:LLY0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score

Get the complete analysis for FRA:LLY0

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.40
Price
€30.80
GF Value